57332-84-0

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 3-bromo-2-oxobutyrate is used as a key intermediate in the synthesis of potential positron emission tomography (PET) tracers for neuropeptide Y Y1 receptors. These tracers are essential for studying the role of neuropeptide Y Y1 receptors in various physiological and pathological processes, including obesity, anxiety, and depression.
Used in Medical Imaging:
In the field of medical imaging, Ethyl 3-bromo-2-oxobutyrate is used as a precursor for the development of PET tracers. PET is a non-invasive imaging technique that allows for the visualization of molecular processes within the body. The tracers synthesized using Ethyl 3-bromo-2-oxobutyrate can help researchers and clinicians better understand the function and distribution of neuropeptide Y Y1 receptors, which can be crucial for the diagnosis and treatment of related conditions.
Chemical Properties:
Ethyl 3-bromo-2-oxobutyrate is a clear, colorless oil with the chemical formula C7H9BrO3. It is a stable compound at room temperature and can be easily manipulated in various chemical reactions due to its functional groups. Its chemical properties make it a versatile building block for the synthesis of more complex molecules, particularly in the pharmaceutical and medical imaging industries.

Synthesis Reference(s)

The Journal of Organic Chemistry, 67, p. 1102, 2002 DOI: 10.1021/jo010630z

Upstream product

• 15933-07-0 Ethyl 2-oxobutanoate 
• 56-23-5 tetrachloromethane 
• 52089-54-0 ethyl 2-hydroxybutyrate 
• 600-18-0 2-Oxobutyric acid 
• 141-78-6 ethyl acetate 

Downstream Products

• 137267-44-8 ethyl 2,5-dimethylthiazole-4-carboxylate 
• 72054-60-5 2-amino-5-methylthiazole-4-carboxylic acid ethyl ester 
• 197719-33-8 5-methyl-4-ethoxycarbonyl-4-oxazolin-2-one 
• 505073-37-0 ethyl 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 505073-86-9 ethyl 2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 796875-23-5 ethyl 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 796875-25-7 ethyl 1-(5-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 505073-79-0 ethyl 2-(2,4-dichlorophenyl)-5-methyl-1-(4-(trifluoromethyl)phenyl)-1H-imidazole-4-carboxylate 
• 572889-87-3 ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 866598-56-3 ethyl 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 930283-35-5 ethyl 1-[4-(benzyloxy)phenyl]-2-(2-chlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 1065099-78-6 ethyl 2-amino-5-methyloxazole-4-carboxylate 
• 80022-73-7 ethyl 2-(4-bromophenyl)-5-methyloxazole-4-carboxylate 
• 1282549-65-8 ethyl 2-formyl-5-methyl-1,3-thiazole-4-carboxylate 

Relevant academic research and scientific papers

Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis

In this study, a series of 49 five-membered heterocyclic compounds containing either a pyridine- or a pyrrole-type nitrogen were synthesized and tested against Mycobacterium tuberculosis. Among them, only the 1,3,5-trisubstituted pyrazoles 5-49 exhibited

PRODRUGS OF ALPHA-KETOGLUTARATE, ALPHA-KETOBUTYRATE, ALPHA-KETOISOVALERATE, AND ALPHA-KETOISOHEXANOATE, AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

AMINOAZOLE DERIVATIVE

A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A- (CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.

PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives

Aiming to discover melanin-concentrating hormone receptor 1 (MCHR1) antagonists with improved safety profiles, we hypothesized that the aliphatic amine employed in most antagonists reported to date could be removed if the bicyclic motif of the compound scaffold interacted with Asp123 and/or Tyr272 of MCHR1. We excluded aliphatic amines from our compound designs, with a cutoff value of pKa 8, and explored aliphatic amine-free MCHR1 antagonists in a CNS-oriented chemical space limited by four descriptors (TPSA, ClogP, MW, and HBD count). Screening of novel bicyclic motifs with high intrinsic binding affinity for MCHR1 identified the imidazo[1,2-a]pyridine ring (represented in compounds 6a and 6b), and subsequent cyclization of the central aliphatic amide linkage led to the discovery of a potent, orally bioavailable MCHR1 antagonist 4-[(4-chlorobenzyl)oxy]-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one 10a. It exhibited low potential for hERG inhibition and phospholipidosis induction as well as sufficient brain concentration to exert antiobesity effects in diet-induced obese rats.

INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compou

Design and synthesis of novel triazole derivatives containing γ-lactam as potential antifungal agents

A series of novel triazole derivatives containing γ-lactam were designed and synthesized, and their structures were confirmed by 1H NMR, 13C NMR and HRMS. The in vitro antifungal activities of the target compounds were evaluated. The results showed that all of the compounds exhibited stronger activity against the six clinically important fungi tested than fluconazole. 3D and 3E showed comparative activity against the fungi tested except for Candida glabrata and Aspergillus fumigatus as voriconazole. In addition, the docking model for 2A and CYP51 was investigated.

5,5-BICYCLIC OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 5,5-bicyclic oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and ps

THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY

The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.

Alternative method for the synthesis of imidazo[5,1-f][1,2,4]triazin-4(3H)- one - A substrate for the preparation of phosphodiesterase (5) inhibitors

Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, as isosteres of purine, are of interest for pharmaceutical research as potential substrates for the synthesis of cGMP-PDE5 inhibitors. We present a novel, alternative method for the synthesis of imidazotriazinones, that differs from the previously reported ones with respect to the method of construction of the triazinone ring in the molecule. The key step in our approach is condensation of an appropriate α-keto-ester with amidrazones, leading to the triazinone heterocycle. Several different substituted imidazolotriazinones have been synthesized in this manner.